Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:21:48.447Z.
Calculation as of: 2026-10-06T16:21:48.447Z.
Quote observation: 2026-10-06T16:04:39.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4d5e19f74cb926d0196b5f3ffb65db8ff8affa0edec331fa5277d4ca2ec73e8d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Decoy Therapeutics Inc.
Market Cap
$845829.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$859931.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$869274.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$869976.00
EV/EBITDA Ratio
N/A
TTM Avg
1464.50x
3Y Avg
6462.34x
5Y Avg
6462.34x
Market Cap
$820321.00
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$809925.00
EV/EBITDA Ratio
N/A
TTM Avg
21.16x
3Y Avg
12.50x
5Y Avg
7.56x
Market Cap
$662826.00
EV/EBITDA Ratio
4.13x
TTM Avg
10.27x
3Y Avg
9.51x
5Y Avg
9.51x
Market Cap
$1.04M
EV/EBITDA Ratio
N/A
TTM Avg
1.21x
3Y Avg
1.21x
5Y Avg
1.21x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | $845829.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $859931.00 | N/A | N/A | N/A | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $869274.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $869976.00 | N/A | 1464.50x | 6462.34x | 6462.34x |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $820321.00 | N/A | N/A | N/A | N/A |
| Ridgetech, Inc. (RDGT)vs › | $809925.00 | N/A | 21.16x | 12.50x | 7.56x |
| CDT Equity Inc. (CDT)vs › | $662826.00 | 4.13x | 10.27x | 9.51x | 9.51x |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.04M | N/A | 1.21x | 1.21x | 1.21x |
| Clearmind Medicine Inc. (CMND)vs › | $1.06M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
